• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology.转移性三阴性乳腺癌的靶向治疗：精准肿瘤学的下一个前沿领域。
Oncotarget. 2017 Nov 21;8(63):106167-106168. doi: 10.18632/oncotarget.22580. eCollection 2017 Dec 5.
2
Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.三阴性乳腺癌中的大汗腺癌：大汗腺型浸润性导管癌为雌激素/孕激素受体阴性、雄激素受体阳性的新型定义。
Jpn J Clin Oncol. 2012 May;42(5):375-86. doi: 10.1093/jjco/hys034. Epub 2012 Mar 26.
3
Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.维生素D与雄激素受体靶向疗法治疗三阴性乳腺癌
Breast Cancer Res Treat. 2016 May;157(1):77-90. doi: 10.1007/s10549-016-3807-y. Epub 2016 Apr 27.
4
Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.乳腺癌治疗的免疫疗法：检查点阻断、癌症疫苗及联合免疫疗法的未来方向
Clin Adv Hematol Oncol. 2016 Nov;14(11):922-933.
5
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.三阴性乳腺癌：新兴的治疗方式和新型联合疗法。
Cancer Treat Rev. 2018 Jan;62:110-122. doi: 10.1016/j.ctrv.2017.11.003. Epub 2017 Nov 13.
6
Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?雄激素受体靶向治疗是否为三阴性乳腺癌的新兴治疗策略？
Cancer Treat Rev. 2015 Jun;41(6):547-53. doi: 10.1016/j.ctrv.2015.04.009. Epub 2015 Apr 29.
7
Palliative systemic therapy for young women with metastatic breast cancer.转移性乳腺癌年轻女性的姑息性全身治疗。
Curr Opin Support Palliat Care. 2015 Sep;9(3):301-7. doi: 10.1097/SPC.0000000000000163.
8
Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.Claudin 4在三阴性乳腺癌中的表达：与雄激素受体及Ki-67表达的相关性
Ann Diagn Pathol. 2015 Feb;19(1):37-42. doi: 10.1016/j.anndiagpath.2014.10.003. Epub 2014 Oct 25.
9
Directed therapy of subtypes of triple-negative breast cancer.三阴性乳腺癌亚型的定向治疗。
Oncologist. 2011;16 Suppl 1:71-8. doi: 10.1634/theoncologist.2011-S1-71.
10
ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy.接受铂类化疗的转移性三阴性乳腺癌患者的ERCC1表达情况
Asian Pac J Cancer Prev. 2017 Feb 1;18(2):507-513. doi: 10.22034/APJCP.2017.18.2.507.

引用本文的文献

1
Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer.抑制 Notch 可增强免疫检查点阻断在三阴性乳腺癌中的疗效。
Sci Adv. 2024 Nov;10(44):eado8275. doi: 10.1126/sciadv.ado8275. Epub 2024 Oct 30.
2
Glutaminase (GLS1) gene expression in primary breast cancer.原发性乳腺癌中的谷氨酰胺酶（GLS1）基因表达。
Breast Cancer. 2023 Nov;30(6):1079-1084. doi: 10.1007/s12282-023-01502-0. Epub 2023 Sep 7.
3
Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130.确定三阴性乳腺癌患者的 PD-L1 状态：来自 IMpassion130 的经验教训。
J Natl Cancer Inst. 2022 May 9;114(5):664-675. doi: 10.1093/jnci/djab121.
4
Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.基于新一代测序的巴基斯坦乳腺癌和卵巢癌种系panel 检测。
Asian Pac J Cancer Prev. 2021 Mar 1;22(3):719-724. doi: 10.31557/APJCP.2021.22.3.719.
5
Kinetic Modeling of F-(24)4-Fluoroglutamine in Mouse Models of Breast Cancer to Estimate Glutamine Pool Size as an Indicator of Tumor Glutamine Metabolism.乳腺癌小鼠模型中 F-(24)4-氟谷氨酸的动力学建模，以评估谷氨酰胺池大小作为肿瘤谷氨酰胺代谢的指标。
J Nucl Med. 2021 Aug 1;62(8):1154-1162. doi: 10.2967/jnumed.120.250977. Epub 2020 Dec 4.
6
Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast Cancer.致癌 TRIM37 连接三阴性乳腺癌的化疗耐药性和转移命运。
Cancer Res. 2020 Nov 1;80(21):4791-4804. doi: 10.1158/0008-5472.CAN-20-1459. Epub 2020 Aug 27.
7
Synergistic Induction of Apoptosis by the Combination of an Axl Inhibitor and Auranofin in Human Breast Cancer Cells.Axl抑制剂与金诺芬联合对人乳腺癌细胞凋亡的协同诱导作用
Biomol Ther (Seoul). 2020 Sep 1;28(5):473-481. doi: 10.4062/biomolther.2020.051.
8
Immunotherapy: A Challenge of Breast Cancer Treatment.免疫疗法：乳腺癌治疗的一项挑战
Cancers (Basel). 2019 Nov 20;11(12):1822. doi: 10.3390/cancers11121822.
9
A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer.基于双特异性抗体的方法靶向三阴性乳腺癌中的间皮素。
Front Immunol. 2019 Jul 10;10:1593. doi: 10.3389/fimmu.2019.01593. eCollection 2019.
10
Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1.抗体药物偶联物 T-DM1 治疗 HER2+乳腺癌会诱导 ROR1 的表达，并通过激活 Hippo 转录共激活因子 YAP1 产生耐药性。
EBioMedicine. 2019 May;43:211-224. doi: 10.1016/j.ebiom.2019.04.061. Epub 2019 May 10.

本文引用的文献

1
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.Ipatasertib联合紫杉醇对比安慰剂联合紫杉醇作为转移性三阴性乳腺癌一线治疗方案（LOTUS）：一项多中心、随机、双盲、安慰剂对照的2期试验
Lancet Oncol. 2017 Oct;18(10):1360-1372. doi: 10.1016/S1470-2045(17)30450-3. Epub 2017 Aug 8.
2
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.奥拉帕利治疗携种系 BRCA 突变的转移性乳腺癌患者。
N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450. Epub 2017 Jun 4.
3
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.抗 Trop-2 抗体药物偶联物赛托珠单抗戈维单抗（IMMU-132）在接受过大量预处理的转移性三阴性乳腺癌患者中的疗效和安全性
J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.
4
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.帕博利珠单抗治疗晚期三阴性乳腺癌患者：Ib期KEYNOTE-012研究
J Clin Oncol. 2016 Jul 20;34(21):2460-7. doi: 10.1200/JCO.2015.64.8931. Epub 2016 May 2.
5
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.局部晚期或转移性乳腺癌患者中抗体药物偶联物 glembatumumab vedotin 的 I/II 期研究。
J Clin Oncol. 2014 Nov 10;32(32):3619-25. doi: 10.1200/JCO.2013.52.5683. Epub 2014 Sep 29.
6
Clonal evolution in breast cancer revealed by single nucleus genome sequencing.单细胞基因组测序揭示乳腺癌中的克隆进化。
Nature. 2014 Aug 14;512(7513):155-60. doi: 10.1038/nature13600. Epub 2014 Jul 30.
7
The clonal and mutational evolution spectrum of primary triple-negative breast cancers.原发性三阴性乳腺癌的克隆和突变进化图谱。
Nature. 2012 Apr 4;486(7403):395-9. doi: 10.1038/nature10933.

Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology.

作者信息

Vidula Neelima, Bardia Aditya

机构信息

Aditya Bardia: Massachusetts General Hospital, Boston, MA, USA.

出版信息

Oncotarget. 2017 Nov 21;8(63):106167-106168. doi: 10.18632/oncotarget.22580. eCollection 2017 Dec 5.

DOI:10.18632/oncotarget.22580
PMID:29290935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5739720/
Abstract
摘要